Mpox in Children: 3 Cases

Irene Frantzis,Stephanie P Ungar,Vijaya L Soma,Dorothy Knutsen,Dana Mazo,Jason Zucker,Stephanie P. Ungar,Vijaya L. Soma
DOI: https://doi.org/10.1542/peds.2022-061047
2024-01-01
PEDIATRICS
Abstract:Although the 2022 mpox outbreak mostly affected adults, its effect on children and adolescents was also substantial. In this report, we describe the clinical course and treatment of the first 3 known cases of mpox in children in New York City. These cases are instructive because they illustrate various routes of transmission, clinical presentations, and diagnostic challenges that differ from previous reports of mpox in endemic countries and previous mpox outbreaks. Of note is that each of the 3 patients received treatment with tecovirimat under an US Food and Drug Administration expanded access investigational new drug application and improved without exhibiting adverse reactions.
pediatrics
What problem does this paper attempt to address?